Major mergers and acquisitions (M&As) in the biopharma industry continue to generate headlines, but last year, funding—particularly in the US—was also highly prominent, with more than $12 billion raised in venture funding during 2018. In this feature, with the help of DealForma, we explore key biopharma deal trends, including M&As, partnerships and venture funding since June 2018.
2019 kicks off with high-value M&As
Since June 2018, over 225 biopharma mergers, acquisitions, and reverse mergers have been announced, with an aggregate value greater than $145 billion. Several deals had particularly high values, and more than 70% of the total transaction value came from just the top ten deals (Table 1).
Four of the top ten deals have been signed since the start of 2019 and were all in the top five for deal value. Bristol-Myers Squibb’s
$74 billion acquisition of Celgene, announced in January 2019, tops the chart, and is the industry’s fourth-largest pharma M&A ever (Nat. Rev. Drug Discov. 18 , 93–94; 2019). The deal could establish the merged company as one of the largest in the oncology field, by combining Bristol-Myers Squibb’s extensive immuno-oncology (IO) pipeline—including one of the leading marketed checkpoint inhibitors, Opdivo (nivolumab)—with Celgene’s blood cancer portfolio. This includes the mega-blockbuster Revlimid (lenalidomide), which had sales of $9.7 billion in 2018 (Nat. Rev. Drug Discov. 18 , 245; 2019). Several other M&As in the top ten were also in the oncology area, including Lilly’s $8 billion acquisition of Loxo Oncology and its pipeline of genomically targeted kinase inhibitors, and GlaxoSmithKline’s $5.1 billion acquisition of Tesaro and its leading product Zejula (niraparib), a poly-ADP ribose polymerase inhibitor that is approved for ovarian cancer.
Finally, two major M&As indicate emerging hot areas for dealmaking beyond oncology: Roche’s $4.3 billion acquisition of gene therapy pioneer Spark Therapeutics, which has recently received landmark regulatory approvals for the ophthalmic gene therapy Luxturna (voretigene neparvovec); and Merrick’s $2.3 billion acquisition of AI Medical Systems in the field of artificial intelligence and machine learning.
Oncology partnerships dominate
Since June last year, ~1,000 biopharma research and development and commercial partnerships have been signed, with a total potential value of ~$100 billion, including $11 billion upfront in cash.
It is no surprise that oncology is the leading therapeutic area for partnerships, with the total potential value of the oncology deals in the period analyzed being three times as much as the total deal value of the second-place therapeutic area, neurology (Fig. 1a). Of the top ten deals (Table 2), seven are in the oncology area, including the top deal signed in March this year between AstraZeneca and Daiichi Sankyo. AstraZeneca agreed to pay ~$1.3 billion upfront and $5.5 billion in potential sales and regulatory milestone payments to partner on Daiichi’s antibody–drug conjugate [Fam-] trastuzumab deruxtecan (DS-8201) as a monotherapy and combination therapy in human epidermal growth factor receptor 2-expressing cancers.
Advances and biopharma interest in IO have contributed to the large increase in oncology dealmaking and deal values, as reviewed in our March edition (BioPharma Dealmakers B3–B6; March 2019). For example, in August 2018, Roche’s Genentech subsidiary partnered with Affimed in a deal worth $5 billion to harness Affimed’s Redirected Optimized Cell Killing (ROCK) platform to develop natural killer cell engager-based immunotherapeutics. Platform deals were also popular, in total making up five of the top ten deals, including four in the oncology area.
Emerging therapeutic modalities
The emergence of recently validated therapeutic modalities beyond small molecules and antibodies (Fig. 1b) is also reflected in recent deals. Last year saw the FDA approval of the first RNA interference (RNAi)-based therapy—Alnylam’s Onpattro (patisiran)—and one of the few top ten deals outside oncology relates to RNAi. In October 2018, Lilly signed a potential $3.7 billion deal with Dicerna Pharmaceuticals through which the companies will use Dicerna’s GalXC RNAi technology platform to develop therapies for cardiometabolic disease, neurodegeneration and pain.
Gene-therapy-related deals were also prominent, including Voyager Therapeutics’ potential $1.8 billion deal with Neurocrine Biosciences signed in January 2019. Neurocrine has gained rights to four neurology-focused gene therapy programs, including VY-AADC, which is in phase 2 trials for Parkinson’s disease.
2018 was a record-breaking year for venture funding, particularly in the US, in which over $12 billion was raised. Since June 2018, more than 300 venture rounds have been completed, raising a total of ~$15 billion worldwide (Box 1).
Surge in venture funding
The top ten raises (Table 3) include companies with products at various development stages. Leading the list is regenerative medicine specialist Samumed, which raised $438 million in an A-6 equity round with investors including Vickers Venture Partners and Family Investors. The company has very recently moved its lead candidate lorecivivint, a small-molecule WNT pathway inhibitor, into a phase 3 trial in knee osteoarthritis.
Among the platform companies in the top ten, Relay Therapeutics raised the highest amount—$400 million—for its protein motion-based drug discovery platform through a series C round contributed to by Softbank, Foresite Capital and others.